361336-80-3

Basic information

• Product Name: Benzeneaceticacid, 3-amino-2,6-difluoro-, methyl ester
• Synonyms: 3-Amino-2,6-difluorobenzeneaceticacid methyl ester;methyl (3-amino-2,6-difluorophenyl)acetate;benzeneacetic acid, 3-amino-2,6-difluoro-, methyl ester
• CAS NO: 361336-80-3
• Molecular Formula: C₉H₉F₂NO₂
• Molecular Weight: 201.1701
• Product Categories: pharmacetical
• Mol File: 361336-80-3.mol

Chemical Properties

• Boiling Point: 267.241 °C at 760 mmHg
• Flash Point: 115.424 °C
• Appearance: /
• Density: 1.315 g/cm³
• Vapor Pressure: 0.008mmHg at 25°C
• Refractive Index: 1.519
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: Benzeneaceticacid, 3-amino-2,6-difluoro-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneaceticacid, 3-amino-2,6-difluoro-, methyl ester(361336-80-3)
• EPA Substance Registry System: Benzeneaceticacid, 3-amino-2,6-difluoro-, methyl ester(361336-80-3)

Safety Data

• Hazardous Substances Data: 361336-80-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Benzeneacetic acid, 3-amino-2,6-difluoro-, methyl ester is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and functional groups make it a promising candidate for the development of new drugs with potential therapeutic applications.
Used in Agricultural Industry:
Benzeneaceticacid, 3-amino-2,6-difluoro-, methyl ester is used as an active ingredient in some agrochemicals, particularly in the development of fungicides and bactericides. Its antifungal and antibacterial properties contribute to the protection of crops from various diseases, thereby enhancing agricultural productivity.
Used in Organic Synthesis:
Benzeneacetic acid, 3-amino-2,6-difluoro-, methyl ester is used as a key building block in the synthesis of various organic compounds. Its versatile structure allows for further functionalization and modification, enabling the creation of a wide range of chemical entities with diverse applications.
It is important to handle Benzeneaceticacid, 3-amino-2,6-difluoro-, methyl ester with care, as it is classified as a hazardous chemical. It has the potential to cause irritation to the skin, eyes, and respiratory system. Proper safety measures should be taken during its production, storage, and use to minimize any adverse effects on human health and the environment.

InChI:InChI=1/C9H9F2NO2/c1-14-8(13)4-5-6(10)2-3-7(12)9(5)11/h2-3H,4,12H2,1H3

Upstream product

• 85068-28-6 2,6-difluorophenylacetic acid 
• 67-56-1 methanol 
• 361336-78-9 (2,6-difluoro-3-nitrophenyl)acetic acid 
• 361336-79-0 methyl (2,6-difluoro-3-nitrophenyl)acetate 

Downstream Products

• 619332-98-8 methyl {3-[bis(benzylsulfonyl)amino]-2,6-difluorophenyl}acetate 
• 361336-89-2 {2,6-difluoro-3-[(2-phenylethyl)amino]phenyl}acetic acid 
• 619332-99-9 {3-[(benzylsulfonyl)amino]-2,6-difluorophenyl}acetic acid 
• 361336-83-6 tert-butyl 4-{[({3-[(benzylsulfonyl)amino]-2,6-difluorophenyl}acetyl)amino]methyl}piperidine-1-carboxylate 
• 361336-90-5 benzyl (4-{[({2,6-difluoro-3-[(2-phenylethyl)amino]phenyl}acetyl)amino]methyl}phenyl)(imino)methylcarbamate 
• 361336-85-8 benzyl (4-{[({3-[(benzylsulfonyl)amino]-2,6-difluorophenyl}acetyl)amino]methyl}phenyl)(imino)methylcarbamate 
• 619333-00-5 benzyl (1Z)-amino(3-{[({3-[(benzylsulfonyl)amino]-2,6-difluorophenyl}acetyl)amino]methyl}phenyl)methylidenecarbamate 
• 619333-01-6 bis-tert-butyl (1E)-amino({5-[({3-[(benzylsulfonyl)amino]-2,6-difluorophenyl}acetyl)amino]pentyl}amino)dimethylidenecarbamate 
• 478618-57-4 methyl 3-(2-pyridylethyl)amino-2,6-difluorophenylacetate 
• 1377455-17-8 C₁₈H₁₈F₂N₄O₃S₂ 
• 1377455-07-6 C₂₁H₂₁F₂N₇O₃S 
• 1377455-04-3 C₂₂H₂₀F₂N₆O₃S 
• 1377455-01-0 C₂₃H₂₁F₂N₅O₃S 

Relevant articles and documents

Design, synthesis and biological evaluation of non-covalent AmpC β-lactamases inhibitors

Abstract: Bacterial resistance represents a worldwide emergency threatening the efficacy of all available antibiotics. Among the several resistance mechanisms developed by bacteria, β-lactamase enzymes?(BLs), which are able to inactivate most β-lactam core antibiotics, represent a key target to block, thus prolonging antibiotics half-life. Several approaches aimed at inhibiting β-lactamases have been so far undertaken, mainly involving β-lactam-like or covalent inhibitors. Applying a structure-based de novo design approach, we recently discovered a novel, non-covalent and competitive inhibitor of AmpC β-lactamase:?lead 1. It has a Ki of 1 μM, a ligand efficiency of 0.38 kcal mol?1 and lead-like physical properties. Moreover, it reverts resistance to ceftazidime in bacterial pathogens expressing AmpC and does not up-regulate β-lactamases expression in cell culture. Its features make it a good candidate for chemical optimization: starting from lead 1 crystallographic complex with AmpC, 11 analogs were designed to complement additional AmpC sites, then synthesized and tested against clinically resistant pathogens. While the new inhibitors maintain similar in vitro activity as the starting lead, some of them, in biological assays, extert a higher potency showing improved synergic activity with ceftazidime in resistant clinically isolated strains. Graphical Abstract: [InlineMediaObject not available: see fulltext.].

Synthesis and crystal structures of substituted benzenes and benzoquinones as tissue factor VIIa inhibitors

Several multistep syntheses of substituted benzenes are reported. The benzene analogues were designed such that their substitution pattern would occupy and interact with the S1, S2, and S3 pockets of the tissue Factor VIIa enzyme. A variety of chemical transformations including nucleophilic additions, reductive aminations, Stille couplings, and polymer-assisted solution-phase (PASP) techniques were used to prepare key intermediates and final products. The initial analogues identified some weakly active compounds which ultimately led to a 340 nM (IC50) tissue Factor VIIa inhibitor with selectivity over other related enzymes. The structure-activity relationship of these inhibitors and the synthetic progression from the discovery of the lead compound to the development of potent analogues will be discussed. The X-ray crystal structures of fluorobenzene 50c and benzoquinone 54 inhibitors complexed with the TF/VIIa enzyme will also be described.